莫哌屈嗪 | 75841-82-6

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 莫哌屈嗪
• 中文别名: 卯匹卓拉
• 英文名称: N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazineamine
• 英文别名: N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine；N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-morpholino-3-pyridazineamine；Mopidralazine；N-(2,5-dimethylpyrrol-1-yl)-6-morpholin-4-ylpyridazin-3-amine
• CAS: 75841-82-6
• 化学式: C₁₄H₁₉N₅O
• 分子量: 273.338
• InChiKey: JBVCSNJKVNKDHK-UHFFFAOYSA-N

物化性质

• 沸点：
  527.5±60.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  55.2
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  乙酸酐 、 莫哌屈嗪 在 乙酸乙酯 、 aqueous solution 、 碳酸氢钠 作用下， 以 吡啶 为溶剂， 反应 1.0h， 生成 N-(2,5-dimethyl-1H-pyrrol-1-yl)-N-<6-(4-morpholinyl)-3-pyridazinyl>acetamide
  参考文献：
  名称：

  N-Pyrrolyl-pyridazineamines and their use as antihypertensive agents

  摘要：

  新的吡咯基-3-吡啶嗪胺类化合物，在位置6上进一步具有氨基取代基。这些化合物可用作降压药物，并可从6-氨基取代-3-肼基吡啶嗪和β-二羰基化合物制备。本发明还声明了将新化合物用作降压药物以及含有新化合物作为活性成分的组合物的用途。

  公开号：

  US04247551A1
• 作为产物：
  描述：

  3(2H)-哒嗪酮,6-(4-吗啉基)-,腙 、 2,5-己二酮 以 溶剂黄146 为溶剂， 反应 3.0h， 以17 g的产率得到莫哌屈嗪
  参考文献：
  名称：

  Antihypertensives. N-1H-Pyrrol-1-yl-3-pyridazinamines

  摘要：

  The hypothesis that the side effects of hydralazine, such as mutagenicity and lupus erythematosus like syndrome, might be due to the NHNH2 group prompted us to incorporate part of this moiety into a pyrrole ring. Therefore, we prepared a series of N-1H-pyrrol-1-yl-3-pyridazinamines and a limited number of N-1H-pyrrol-1-yl-1-phthalazinamines by reaction of 3-hydrazinopyridazines and 1-hydrazinophthalazines with gamma-diketones. Most of these compounds, especially in the pyridazine series, showed moderate to strong antihypertensive activity in spontaneously hypertensive rats. The decrease in blood pressure generally had a slow onset after either oral or intravenous administration. N-(2,5-Dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride (30) (MDL 899) showed no mutagenic activity in several tests and is now in clinical trials in patients.

  DOI：

  10.1021/jm00374a024

文献信息

• Process for preparing N-pyrrolyl-pyridazineamine derivatives
  申请人：Gruppo Lepetit S.p.A.

  公开号：US04385179A1

  公开（公告）日：1983-05-24

  The present invention refers to a new process for preparing N-2,3,4,5-substituted-1H-pyrrol-1-yl)-6-substituted amino-3-pyridazineamine, known as antihypertensive agents. The process is characterized in that a suitable 3,6-dihalogenopyridazine is reacted with hydrazine hydrate or other hydrazine derivatives of formula NH.sub.2 NHR, the obtained compound is reacted with a suitable dicarbonyl compound yielding first an alcandione-bis-[6-halogen-3-pyridazininyl]hydrazone, and then a 6-halogen-3-pyrrolylpyridazineamine derivative which is in turn reacted with an amine to yield the desired compounds.

  本发明涉及一种制备N-2,3,4,5-取代-1H-吡咯-1-基)-6-取代氨基-3-吡啶嗪胺的新工艺，该化合物被称为降压药物。该工艺的特点在于，将适当的3,6-二卤吡啶与水合肼或其他式为NH.sub.2 NHR的肼衍生物反应，得到的化合物与适当的二羰基化合物反应，首先生成一种alcandione-双-[6-卤-3-吡啶嗪基]肼酮，然后生成一种6-卤-3-吡咯基吡啶嗪胺衍生物，该衍生物再与胺反应以得到所需的化合物。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• 6-Amino substituted N-pyrrolyl-3-pyridazine amines, their preparation, and pharmaceutically antihypertensive compositions containing them
  申请人：GRUPPO LEPETIT S.P.A.

  公开号：EP0009655A1

  公开（公告）日：1980-04-16

  New N-pyrrolyl-3-pyridazine-amines having a further aminic substituent in the 6 position of the formula (I), wherein R, R1, R2 and R3 are hydrogen or lower alkyl, R4 is e.g hydrogen or lower alkyl, R5 and R6 are e.g. lower alkyl or taken together with the adjacent nitrogen atom represent a saturated 5 - 6 membered heterocyclic ring which may contain a further heteroatom, R7 and R8 represent hydrogen or, taken together, a 1,3-butadienylene radical forming a benzo system fused with the pyridazine ring, for example N-2,5-dimethyl-1H-pyrrol-1-yl)- 6-morpholino-3-pyridazineamine or N-(2,5-dimethyl-1H-pyrrol- 1-yl)-4-(4-hydroxypiperidino)-1-phthalazineamine, and their pharmaceutically acceptable salts are made e.g. by contacting a hydrazino derivate of the formula (II), wherein the substituents have the same meaning as above or an acid addition salt thereof with a dicarbonyl compound of the formula (III), wherein the substituents have the same meaning as above, or a functional derivative thereof in the presence of an acid catalyst at a temperature between 15°C and 120°C. The new compounds can be used as antihypertensive agents.

  在式 (I) 的 6 位具有另一个氨基取代基的新型 N-吡咯烷-3-哒嗪胺、 其中 R、R1、R2 和 R3 为氢或低级烷基，R4 如为氢或低级烷基，R5 和 R6 如为R5和R6是低级烷基，或与相邻的氮原子一起代表一个饱和的 5 - 6 个成员的杂环，该杂环可能含有另一个杂原子，R7和R8代表氢，或与 1、例如 N-2,5-二甲基-1H-吡咯-1-基）-6-吗啉基-3-哒嗪胺或 N-(2,5-二甲基-1H-吡咯-1-基)-4-(4-羟基哌啶基)-1-酞嗪胺及其药学上可接受的盐。例如，将式（II）的肼基衍生物（其中取代基的含义同上）或其酸加成盐与式 （III）的二羰基化合物（其中取代基的含义同上）或其官能衍生物在酸催化剂存在下于 15°C 至 120°C 的温度下接触。 新化合物可用作降压药。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY
  申请人：Scidose, Llc

  公开号：EP1954244A1

  公开（公告）日：2008-08-13